Mualliflar

  • Kodirova Sh.K.
  • Kenzhaev M.L.

##semicolon##

ischemic heart failure, HFrEF, dobutamine stress echocardiography, myocardial viability, contractile reserve.

##submission.citations##

1. Babes EE, Tit DM, Bungau AF, et al. Myocardial Viability Testing in the Management of Ischemic Heart Failure. Life (Basel). 2022;12(11):1760. doi:10.3390/life12111760.

2. Heusch G. Myocardial stunning and hibernation revisited. Nat Rev Cardiol. 2021; 18(7):522–536. doi:10.1038/s41569-021-00506-7.

3. Katikireddy CK, Samim A. Myocardial viability assessment and utility in contemporary management of ischemic cardiomyopathy. Clin Cardiol. 2022;45(2):152–161. doi:10.1002/clc.2 3779.

4. Kheiri B, et al. The Utility of Low-Dose-Dobutamine Stress Echocardiography in Patients with Heart Failure with Reduced Ejection Fraction: An Update. J Clin Med. 2023.

5. Kourek C, et al. Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium. Int J Mol Sci. 2024;25(6):3113. doi:10.3390/ijms25063113.

6. Kwon DH, et al. Myocardial viability assessment and utility in contemporary management of ischemic cardiomyopathy. Clin Cardiol. 2022;45:152–161.

7. Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020;324(5):488–504. doi:10.1001/jama.2020.10262

8. Panza JA, Chrzanowski L, Bonow RO. Myocardial Viability Assessment Before Surgical Revascularization in Ischemic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;78(10):1068–1077. doi:10.1016/j.jacc.2021.07.004

9. Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, et al. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med. 2021;8:75449